ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Entrada Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 4.89%
- The company has been able to generate a Return on Equity (avg) of 4.89% signifying low profitability per unit of shareholders funds
2
With a fall in Net Profit of -795.74%, the company declared Very Negative results in Jun 25
- The company has declared negative results for the last 2 consecutive quarters
- The company has declared negative results in Dec 24 after 7 consecutive negative quarters
- OPERATING CASH FLOW(Y) Lowest at USD -123.87 MM
- DEBT-EQUITY RATIO (HY) Highest at -78.86 %
- RAW MATERIAL COST(Y) Grown by 56.56% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -36.46%, its profits have risen by 5.5%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -36.46% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Entrada Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Entrada Therapeutics, Inc.
-36.46%
-0.48
62.02%
S&P 500
16.49%
0.83
19.88%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
331.75%
EBIT Growth (5y)
-7.16%
EBIT to Interest (avg)
-17.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.39
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
89.49%
ROCE (avg)
4.98%
ROE (avg)
4.89%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.76
EV to EBIT
-14.66
EV to EBITDA
-7.68
EV to Capital Employed
-1.46
EV to Sales
-0.35
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
5.94%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-38What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -123.87 MM
DEBT-EQUITY RATIO
(HY)
Highest at -78.86 %
RAW MATERIAL COST(Y)
Grown by 56.56% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 12.76 times
NET SALES(Q)
Lowest at USD 1.95 MM
OPERATING PROFIT(Q)
Lowest at USD -43.85 MM
OPERATING PROFIT MARGIN(Q)
Lowest at -2,248.67 %
PRE-TAX PROFIT(Q)
Lowest at USD -41.02 MM
NET PROFIT(Q)
Lowest at USD -41.2 MM
EPS(Q)
Lowest at USD -1.04
Here's what is working for Entrada Therapeutics, Inc.
Depreciation
Highest at USD 1.1 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Entrada Therapeutics, Inc.
Net Sales
At USD 1.95 MM has Fallen at -95.47%
over average net sales of the previous four periods of USD 43.05 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -41.02 MM has Fallen at -789.24%
over average net sales of the previous four periods of USD 5.95 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -41.2 MM has Fallen at -765.07%
over average net sales of the previous four periods of USD 6.2 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -123.87 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Highest at -78.86 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Net Sales
Lowest at USD 1.95 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Operating Profit
Lowest at USD -43.85 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Operating Profit Margin
Lowest at -2,248.67 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at USD -41.02 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -41.2 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD -1.04
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Lowest at 12.76 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 56.56% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
